197 related articles for article (PubMed ID: 15138894)
1. Kinematical analysis of motor function in schizophrenic patients: a possibility to separate negative symptoms from extrapyramidal dysfunction induced by neuroleptics?
Henkel V; Mergl R; Schäfer M; Rujescu D; Möller HJ; Hegerl U
Pharmacopsychiatry; 2004 May; 37(3):110-8. PubMed ID: 15138894
[TBL] [Abstract][Full Text] [Related]
2. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
Honer WG; Kopala LC; Rabinowitz J
J Psychopharmacol; 2005 May; 19(3):277-85. PubMed ID: 15888513
[TBL] [Abstract][Full Text] [Related]
3. [Neurological soft signs in schizophrenic patients and their nonaffected siblings].
Mechri A; Slama H; Bourdel MC; Chebel S; Mandhouj O; Krebs MO; Gaha L
Encephale; 2008 Oct; 34(5):483-9. PubMed ID: 19068337
[TBL] [Abstract][Full Text] [Related]
4. Motoric neurological soft signs and psychopathological symptoms in schizophrenic psychoses.
Jahn T; Hubmann W; Karr M; Mohr F; Schlenker R; Heidenreich T; Cohen R; Schröder J
Psychiatry Res; 2006 Jun; 142(2-3):191-9. PubMed ID: 16650902
[TBL] [Abstract][Full Text] [Related]
5. [Three-dimensional ultrasonic movement analysis of gait and hand-movements in schizophrenic patients].
Putzhammer A; Perfahl M; Pfeiff L; Müller JL
Psychiatr Prax; 2005 Apr; 32 Suppl 1():S38-42. PubMed ID: 15818519
[TBL] [Abstract][Full Text] [Related]
6. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
7. Correlation of subjective well-being in schizophrenic patients with gait parameters, expert-rated motor disturbances, and psychopathological status.
Putzhammer A; Perfahl M; Pfeiff L; Hajak G
Pharmacopsychiatry; 2005 May; 38(3):132-8. PubMed ID: 15902585
[TBL] [Abstract][Full Text] [Related]
8. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
9. [Digitized analysis of hand movements in psychiatry. Methods, clinical findings and perspectives].
Mergl R; Tigges P; Schröter A; Hegerl U
Fortschr Neurol Psychiatr; 2000 Sep; 68(9):387-97. PubMed ID: 11037637
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
11. Predictors of subjective and objective quality of life in outpatients with schizophrenia.
Yamauchi K; Aki H; Tomotake M; Iga J; Numata S; Motoki I; Izaki Y; Tayoshi S; Kinouchi S; Sumitani S; Tayoshi S; Takikawa Y; Kaneda Y; Taniguchi T; Ishimoto Y; Ueno S; Ohmori T
Psychiatry Clin Neurosci; 2008 Aug; 62(4):404-11. PubMed ID: 18778437
[TBL] [Abstract][Full Text] [Related]
12. [Vitamin B6 add-on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders].
Miodownik C; Cohen H; Kotler M; Lerner V
Harefuah; 2003 Sep; 142(8-9):592-6, 647. PubMed ID: 14518160
[TBL] [Abstract][Full Text] [Related]
13. Triiodothyronine may be possibly associated with better cognitive function and less extrapyramidal symptoms in chronic schizophrenia.
Ichioka S; Terao T; Hoaki N; Matsushita T; Hoaki T
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):170-4. PubMed ID: 22750309
[TBL] [Abstract][Full Text] [Related]
14. Motor behavior abnormalities in drug-naïve patients with schizophrenia spectrum disorders.
Peralta V; Campos MS; De Jalón EG; Cuesta MJ
Mov Disord; 2010 Jun; 25(8):1068-76. PubMed ID: 20222137
[TBL] [Abstract][Full Text] [Related]
15. A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia.
Perez V; Cañas F; Tafalla M;
Int Clin Psychopharmacol; 2008 May; 23(3):138-49. PubMed ID: 18408528
[TBL] [Abstract][Full Text] [Related]
16. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
[TBL] [Abstract][Full Text] [Related]
17. Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol.
Kim JH; Byun HJ
J Clin Pharm Ther; 2007 Oct; 32(5):461-7. PubMed ID: 17875112
[TBL] [Abstract][Full Text] [Related]
18. Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol.
Sa AR; Hounie AG; Sampaio AS; Arrais J; Miguel EC; Elkis H
Compr Psychiatry; 2009; 50(5):437-42. PubMed ID: 19683614
[TBL] [Abstract][Full Text] [Related]
19. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
[TBL] [Abstract][Full Text] [Related]
20. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
